The White House on Thursday announced the formulation of the National Bioeconomy Blueprint, aimed at shoring up the U.S. commitment to bioscience-related research.
But critics warn that the new program focuses too much on economic concerns, placing too little emphasis on either social issues or on the environment itself.
"We're disappointed to see what finally came out," Eric Hoffman, a Washington-based campaigner with Friends of the Earth, an international NGO, told IPS. "This report largely seems to be an endorsement for the biotechnology industry to rush ahead without any real oversight."
The biotechnology industry "says that it has been calling for this type of legislation for long time," Hoffman notes. "That makes sense, given that the industry stands to gain the most from the types of policies laid out in the Blueprint."
Hoffman says that the biotechnology industry includes many of the largest oil and petrochemical producers – ExxonMobil, BP, Chevron, Monsanto, Dow. The lack of plans for government regulation apparent in the Blueprint leaves him pessimistic that much "clean, green" technology will come out of the new effort.
Read More: